Hemophilia - Promising Early Clinical Trials For Longer Acting Kogenate® Product

Mon, 29 May 2006 11:00 AM EST

... Data from two early-stage clinical trials presented today at the World Federation of Hemophilia conference offer promising results and support further development for a new experimental factor VIII replacement product, BAY 79-4980. The findings suggest that this new product may offer people with hemophilia A (factor VIII deficiency) prolonged protection from bleeding with once-weekly infusions. [click link for full article] ...